Two States Require Industry To Pay For Ongoing Drug Take-Back Programs
This article was originally published in The Pink Sheet & The Rose Sheet
Executive Summary
Consumer Healthcare Products Association looks to stem expansion of state-mandated drug take-back programs with programs that use existing facilities and infrastucture and don't require industry funidng, says state affairs VP Carlos Gutierrez. State bills limiting sales of DXM to minors and expansion of the NPLEx system to track PSE sales also are on CHPA’s radar.
You may also be interested in...
CHPA Optimistic Voluntary Drug Takeback Efforts Will Stall Spread Of Mandates
OTC industry trade groups will more aggressively push for an education program to encourage proper disposal of Rx and OTC drugs as states consider mandating industry-funded takeback programs and a patchwork of local ordinances expands.
NPLEx Brings A ‘Quiet’ Year On State PSE Legislation – CHPA
CHPA President and CEO Scott Melville says 2015 is the “quietest” in five years for state legislation on the sale of pseudoephedrine, a testament to NPLEx. Bills for Rx-only PSE sales introduced in four states this year failed.
MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In
The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.